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Abstract 
 
Pancreatic adenocarcinoma has a very poor prognosis with currently existing 
therapies prolonging patient life for only a few weeks. Therefore novel therapy 
options are urgently needed. Present theories maintain that only a small fraction of 
tumour cells (the cancer stem cells (CSC)) are responsible for the highly aggressive 
behaviour of pancreatic cancer. These cells show a stem cell like phenotype and a 
high resistance to chemotherapy. 
Oncolytic viruses are promising candidates for therapeutic agents. Besides being 
replicated inside of host cells they can be attenuated to malignant cells and armed 
with therapeutic genes that will be translated by infected cells. The viruses used in 
this project were provided by our cooperation partner Dr Nettelbeck. The group of Dr 
Nettelbeck examined infection parameters and oncolytic activity of the viruses and 
optimized them for replication and release in mesenchymal stem cells (MSC). 
Additionally I could demonstrate an efficient elimination of pancreatic CSC in vitro.  
A major issue limiting the efficiency of virus therapies so far is their delivery.  
Systemic injected viruses are cleared from the blood by the liver and inactivated by 
the immune system. To overcome this disadvantage MSC isolated from the bone 
marrow were used in the present project to enhance delivery and shield the viruses 
from the host’s immune system. MSC exhibit a strong homing ability towards tumour 
tissue. Migration assays in vitro ascertained that homing is still present after infection 
with the oncolytic adenoviruses.  
As a model for in vivo experiments xenografts transplanted to fertilized chicken eggs 
were used which grow as stroma-enriched tumours. The invasion of tumour 
transplants in vivo was successfully demonstrated after injection of infected MSC into 
blood vessels. In this model I could show that infection with an oncolytic adenovirus 
markedly reduced tumour growth. The infected tumours exhibited a strong cytopathic 
effect with altered morphology.  
The potency of tumour growth reduction strongly depended on the applied 
adenovirus after injection of the infected MSC. Viruses with enhanced lytic or anti-
tumourigenic activity showed a superior performance, while an unmodified virus did 
not reduce tumour growth. The strongest anti-tumourigenic effect was found for a 
TRAIL expressing virus. This was confirmed by a reduction of proliferation and CSC 
marker expression and elevation of apoptosis. Therefore, the application of oncolytic 
	  	  
adenoviruses using MSC as cell carriers seems to be a promising strategy in 
combating pancreatic cancer, especially when viruses with enhanced anti-tumour 
effects are used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
Zusammenfassung 
 
Das Adenokarzinom der Bauchspeicheldrüse weist eine sehr schlechte Prognose 
auf.  Eine Chemotherapie verlängert das Überleben der Patienten meist nur um 
wenige Wochen. Daher besteht eine hohe Priorität in der Entwicklung neuer, 
effektiver Wirkstoffe. Laut neuer Theorien ist vor allem ein kleiner Teil der 
Tumorzellen, die sog. Krebsstammzellen (CSC) für Therapieresistenz und Rezivität 
verantwortlich. Diese Zellen weisen einen stammzellähnlichen Phänotyp auf und 
werden nur schlecht von herkömmlichen Therapien bekämpft. 
Ein vielversprechender neuer Wirkstoff sind onkolytische Adenoviren. Diese können 
modifiziert werden, um maligne Zellen effizient zu infizieren und zu eliminieren. 
Außerdem können Gene für andere Wirkstoffe in die Viren eingefügt werden und ihre 
Wirksamkeit so weiter gesteigert werden. Die in dieser Arbeit verwendeten Viren 
wurden von der Gruppe von Dr. Nettelbeck konstruiert. Diese Arbeit wurde in 
Kooperation mit der AG Nettelbeck durchgeführt. Seine Gruppe untersuchte die 
Infektionseffizienz und onkolytische Aktivität in unterschiedlichen Zelllinien und 
optimierte die Viren für Replikation und Freisetzung in mesenchymalen Stammzellen 
(MSC). Darüberhinaus konnte ich eine effiziente Eliminierung pankreatischer CSC in 
vitro zeigen. 
Ein limitierender Faktor bei Virustherapien ist der Transport der Viren. Diese werden 
in der Leber abgebaut und vom Immunsystem inaktiviert. In dieser Arbeit wurde die 
Effizienz des Transports durch den Einsatz von MSC als Virusträger untersucht. 
Diese Zellen, die aus dem Knochenmark isoliert werden, wandern in Tumorgewebe 
ein, wie in mehreren Publikationen gezeigt wurde. Mittels eines Migrationsassays 
wurde hierbei sichergestellt, dass eine Infektion die Invasionsfähigkeit der MSC nicht 
beeinträchtigt. 
Darüberhinaus konnte die Einwanderung virusinfizierter MSC in vivo gezeigt werden. 
Hierbei wurden Tumorzelltransplantate auf Hühnerbruteiern als in vivo Model 
verwendet. Die wachsenden Tumore werden von Hühnerblutgefäßen durchwachsen 
und entwickeln Tumore, deren Morphologie dem von Patiententumoren ähnelt. Eine 
Infektion durch einen onkolytischen Adenovirus verringerte in diesem Model das 
Tumorwachstum beträchtlich. Die infizierten Tumore zeigten darüberhinaus eine 
stark veränderte Morphologie.   
	  	  
Bei Injektion infizierter MSC, in zum Tumor führende Blutgefäße, zeigten 
verschiedene Adenoviren unterschiedliche Wirkungen. Während ein Virus ohne 
erhöhte anti-tumorigene Wirkung unwirksam war, reduzierten Viren mit erhöhten anti-
tumor Eigenschaften das Wachstum der Tumore. Insbesondere ein TRAIL 
exprimierender Virus erwies  sich als effektiv. Diese Ergebnisse zeigen, dass mittels 
MSC transportierte onkolytische Adenoviren vielversprechende Wirkstoffe einer 
neuen Therapie des Bauchspeicheldrüsenkrebses darstellen. 
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1. Abbreviations 	  	  
5-FU    5-fluorouracil 
ABC 
AEC      
ATP-binding cassette transporters 
Sodium POE 10 fatty alcohol ether carboxylate
Ad      Adenovirus
ALDH    Aldehyde dehydrogenase 
BCIP     5-Bromo-4-chloro-3-indolyl phosphate
CAM    Chorioallantoic membrane 
CAR   Coxsackie-Adenovirus receptor 
CD      Cluster of differentiation 
c-Met   Met proto-oncogene (hepatocyte growth factor 
receptor) 
CNS 
CSC    
Central nervous system 
Cancer stem cell 
CXCR   CXC chemokine receptor 
DMEM    Dulbecco’s modified eagle medium 
DNA   Desoxyribonucleic acid 
DPBS   Dulbecco’s phosphate buffered saline 
DMSO  Dimethylsulphoxid 
EDTA   Ethylenediaminetetraacetic acid 
EGF      Epidermal growth factor 
EMT     Epithelial-mesenchymal transition 
ESA   Epithelial cell adhesion molecule
FACS    Fluorescence-activated cell sorting 
FCS   Fetal calf serum 
FGF  Fibroblast growth factor 
FITC     Fluorescein isothiocyanate 
GFP  Green fluorescent protein 
HEPES  2-hydroxyethyl-piperazinyl-2-ethansulfonicacid 
IFN-β    Interferon type I
IgG           Immunoglobulin G 
K-FSM   Keratinocyte-serum free medium  
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Ki67   Antigen identified by monoclonal antibody Ki-67 
MDR    Multidrug resistance 
MSC      Mesenchymal stem cells 
NBT      Nitro blue tetrazolium chloride 
PBS      Phosphate buffered saline 
PDAC  Pancreatic ductal adenocarcinoma 
PFA    Paraformaldehyde 
RT         Room temperature 
SD       Standard deviation      
TBS Tris-buffered saline 
TCID50    50% Tissue Culture Infective Dose 
TRAIL TNF-related apoptosis-inducing ligand
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Units 
 
Å    angstrom 
°C degree Celsius 
d days 
g gram 
g acceleration relative to free-fall (standard gravity) 
h hours 
IU international unit 
kB kilo-base pair 
l litre 
m metre 
M Molar concentration (molarity) 
min minutes
rpm rounds per minute
s seconds 
U   enzyme unit
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2. Introduction
 
2.1 Pancreatic cancer 
While recent decades have seen an improvement in the treatment and survival rates 
of many cancer varieties this is not true for pancreatic adenocarcinoma, the most 
common malignancy of the pancreas. The overall 5-year survival rate for this 
malignant disease is less than 4% and treatment with the most common 
chemotherapy agent gemcitabine results in only a moderate improvement of survival 
[1]. The growth of pancreatic cancer is asymptomatic until late stages. Thus the 
disease is often diagnosed in an advanced state when metastases are already 
present in most cases. Therefore surgery, which is the only curative option available, 
is not possible in a great majority of patients [2]. Even with surgical removing of the 
tumour the 5-year survival rate is only 20-25% with recurrence being common [3]. 
Although a few risk factors for pancreatic cancer have been identified, data remains 
inconclusive in many cases [4]. The best-established risk factor remains tobacco 
smoking [5], which increases risk for pancreatic cancer significantly, even long after 
quitting [6]. Another known risk factor is the presence of chronic inflammatory 
pancreatitis [7].  
In all cases when the tumour is inoperable or recurrent only palliative therapies exist 
at the moment. Although the most popular chemotherapy agent gemcitabine offers a 
significant increase in survival, the overall survival remains under one year [8]. This 
remains true even when gemcitabine is combined with other agents like Nab-
paxlitaxel or oxaliplatin. These combined therapies show only slightly improved 
performance and due to stronger side effects can only be used with patients in good 
physical condition. Additionally response rates remain poor for all therapies used. 
Drug delivery to pancreatic tumours has been demonstrated to be low. PDAC 
contains extensive stromal tissue that is poorly vascularized and perfused shielding 
the tumour from harmful compounds [9]. The therapy protocol with the biggest 
improvement in overall survival, the FOLFIRINOX regimen consisting of a 
combination of three agents shows strong side effects limiting patient quality of life 
and its usefulness [10].  
	  	  
5	  
With the poor performance of today’s therapies the development of novel effective 
therapy agents remains an important task. 
 
2.2 Pancreatic cancer stem cells 
The high presence of cancer stem cells (CSC) in pancreatic adenocarcinoma could 
be a major reason for the high resistance to conventional therapies this malignancy 
exhibits. CSC were identified in various tumour types including CNS, breast, 
prostate, melanoma and pancreas [11]. Solid tumours are heterogeneous, with many 
different kinds of cells present in the tumour tissue. The great bulk of malignant cells 
in a tumour are non-CSC cells. The CSC constitute only a small fraction of tumour 
cells. However these cells exhibit a much stronger tumour initiating potential than the 
more differentiated tumour cells. They have a high self-renewal capacity and are 
thought to be mostly responsible for tumour progression and metastasis [12, 13]. 
 
 
Figure 1: Role of CSC in tumourigenesis and cancer therapy (adapted from [14])  
 
Besides their tumour-initiating abilities CSC are also highly resistant towards 
chemotherapy [15]. They express a high level of genes coding for ABC transporters 
and ALDH enzymes. This enables them to expel and inactivate cytotoxic substances 
[16]. This characteristic is shared with normal stem cells. Further characteristics 
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shared with stem cell include the expression of many stem cell markers. Many of 
these marker genes are engaged in self-renewal. CSC self-renewal and their 
uncommitted state are maintained by signal pathways also involved in maintenance 
and regulation of normal stem cells like the Wnt/β-catenin, Hedgehog or Notch 
pathways [17, 18]. Like in the case of stem cells a specific microenvironment is 
involved in the regulation of CSC behaviour. Signals from nearby non-malignant 
stromal cells can support either an uncommitted state or differentiation of the CSC, 
thus forming a specific CSC niche [19]. The origin of CSC is debated. Theories 
include development from aberrant normal stem cells or from differentiated cells 
through EMT processes [20, 21]. Both mechanisms are likely to be occurring in 
different tumours. The acquisition of CSC characteristics by differentiated tumour 
cells under certain circumstances was demonstrated [22]. The varying origins of CSC 
show that this cell population is not entirely homogenous in itself. In accordance to 
this markers for CSC differ between tumour types and even between CSC 
subpopulations in one tumour. The data for the relevance of many markers are 
therefore controversial [23]. The most commonly used markers for pancreatic CSC 
are CD24 and CD44. CSC are hereby defined as cells exhibiting a 
CD24+/CD44+/ESA+ phenotype [24]. Other markers used for identification of 
pancreatic CSC include ALDH-1 activity, or the expression of nestin, CD133 or 
CXCR-4 [25, 26]. A recently discovered marker for pancreatic CSC is the tyrosine 
kinase receptor c-Met [27]. Cells exhibiting high levels of c-Met expression showed 
also strong tumorigenic potential. Moreover a high c-Met expression in PDAC is 
correlated with a poor prognosis and with invasion [28].  
 
2.3 Oncolytic viruses in cancer therapy 
Viruses infect and destroy animal and human cells with great efficiency. This ability 
can be exploited for the elimination of malignant cells in patients. Although an anti-
tumour effect of certain virus strains was observed a century ago efforts to use 
viruses for cancer therapy met with poor success [29]. The therapies showed low 
efficiency and risked severe side effects. But with the advent of genetic manipulation 
capabilities it is now possible to create viruses optimized for infection and lysis of 
tumour cells. 
Currently viruses from many different strains are used for establishing virotherapies, 
some of which have proceeded to clinical trials. Viruses employed include 
	  	  
7	  
adenovirus, herpes virus, parvovirus and others [30]. One of the most commonly 
applied viruses is the herpes simplex virus. It has been used in clinical trials for 
different tumours, e.g. melanoma or glioma [31]. In a trial with metastatic melanoma 
complete regression was observed in a few cases. Another commonly used virus is 
the measles virus from the family Paramyxoviridae. It shows natural oncolytic activity 
and targets preferentially malignant cells [32]. In contrast other strains utilized in 
virotherapy like adenovirus or herpes virus do not exhibit a preference for cancer 
cells and show no natural oncolytic activity. However, they can be attenuated to 
malignant cells. One potential method is to modify the virus to recognize and attach 
to a different receptor protein for cell entry. Proteins that are expressed preferentially 
by malignant cells are excellent candidates for such modifications. Other possibilities 
are regulation of virus replication by promoters only being active in malignant cells or 
modification of immune-evasion proteins [33]. Such modifications restrict efficient 
replication and/or virus entry to transformed cells and protect normal cells. Besides 
targeting cancer cells their efficient elimination by the oncolytic virus is crucial for 
therapy response. One problem in the development of oncolytic viruses described is 
the narrow species range of the viruses, making comparison between animal models 
and patients difficult. So far therapy results in clinical trials have been promising, 
although efficacy has still to be increased for clinical use [34]. The studies 
demonstrated also the safety of virotherapy as only minor toxicity from the used virus 
strains has been reported. To enhance antitumor efficiency armed viruses have been 
developed. In this viruses additional therapeutic genes have been cloned which are 
expressed in host cells and released upon cell lysis. With such a Bystander-effect 
also cells not directly infected can be eliminated. Additionally genes affecting the 
tumour microenvironment like proteases can be used [35]. With this enhanced virus 
spread or a modified tumour angiogenesis can be achieved. Besides the direct killing 
of malignant cells oncolytic viruses induce an immune response against the tumour 
tissue, making them also promising agents for cancer immunotherapy and adding a 
further target for enhancing antitumor activity [36]. A protein used for arming oncolytic 
viruses is the tumour necrosis factor (TNF)-related apoptosis-inducing ligand TRAIL. 
TRAIL activates death receptors and induces apoptosis in malignant cells due to 
activation of the extrinsic apoptotic pathway. While targeting malignant cells it shows 
no significant cytotoxicity in normal cells [37]. Oncolytic adenovirus constructs 
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expressing TRAIL showed enhanced anti-tumour activity in malignant glioma and 
hepatoma when compared to the unarmed virus [38, 39] 
A modified adenovirus is frequently employed as the oncolytic agent in virotherapies. 
There have been clinical trials for different malignancies utilizing this virus [40-42]. 
Adenovirus causes most often infections of the respiratory tract, most commonly in 
children. Infections for the most part produce symptoms similar to the common cold, 
although symptoms of adenovirus infection can vary. More severe cases have been 
described, especially in people with suppressed immune system like organ transplant 
recipients [43]. Adenovirus is a member of the family Adenoviridae. It is a highly 
variable virus including over 60 described serotypes in humans divided among seven 
species (named A – G) [44]. The most therapeutically applied serotype is Ad 
serotype 5 (Ad5), which is used almost exclusively for virotherapy [45]. Adenoviruses 
are large (ca. 950 Å) non-enveloped viruses. Their genome consists of dsDNA. It is 
contained in an icosahedral protein capsid. The capsid consists of two different 
subunits: hexons and pentons. The pentons form the vertices and are the basis of 
the fibre domains, which comprise a shaft ending in a knob-domain [46].                
                                 
Figure 2: Structure of an adenovirus (adapted from [47]) 
 
The fibre knob domain is highly involved in adhesion to host cells. In most Ad 
varieties it binds with strong affinity to the Coxsackie Adenovirus Receptor (CAR) 
initializing virus entry. Exceptions are members of adenovirus species B that use 
	  	  
9	  
CD46 for binding to cells. CD46 is a receptor present on the surface of all nucleated 
cells, shielding them from autologous immune reactions. Other known molecules 
used by some Ad serotypes alternatively for cell entry include integrins, sialic acid 
and desmoglein 2 [48]. Unfortunately, CAR is down regulated in many tumours 
reducing Ad affinity. CAR expression however varies strongly between different 
tumour types [49]. The loss of CAR expression and alternations in its subcellular 
distribution have been correlated with tumour progression in some cancers, e.g. in 
colon cancer [50]. While absence of CAR limits infection this could be overcome in 
CAR deficient melanoma cells by switching the fibre domain of Ad5 with that of Ad3. 
As a member of species B Ad3 does not use CAR for adhesion. The chimeric Ad 
showed efficient infection and oncolysis of the melanoma cells independent of CAR 
[51].  
 
 
Figure 3: Simplified Ad5 genome (adapted from [52]) 
 
The adenoviral genome is about 30 – 40 kB long and about 36kB in Ad5. It codes for 
approximately 39 genes. The genes can be divided into early genes and late genes, 
depending on the time point of their expression. The early genes are expressed 
before DNA replication and are responsible for modifying the host cell, activating 
other virus genes or evading immune response. The late genes encode mostly for 
virion proteins and are expressed after DNA replication [52]. An example of host cell 
modification is repression of p53 activity by a product of early gene region E1B, the 
E1B55K protein. It also plays a role in protection of viral replication from inhibition by 
interferon type1 [53]. Apoptosis is prevented by another product of this early gene, 
E1B19K, in infected cells [54]. Another proteins, the E1A proteins, deregulate the cell 
cycle by interaction with Retinoblastoma protein and its target transcription factor 
[55]. They induce DNA replication in quiescent cells with strongly altered replication 
kinetics [56]. Modification of early genes offers another path of virus attenuation. An 
oncolytic adenovirus with mutations in the E1A region and in E1B19K has been 
	  	  
10	  
shown to efficiently replicate and eliminate several malignant cell types [57]. In 
contrast its replication in non-malignant cells was strongly reduced. As cell cycle and 
apoptosis pathways are deregulated in malignant cells viral proteins acting on these 
pathways in normal cells are often redundant in this case.  
In addition to the problems mentioned above which reduce the efficiency of oncoviral 
therapies another obstacle which has to be overcome is an inefficient delivery of the 
viruses. Systemic application of oncolytic viruses results in only a small fraction of 
them reaching the tumour [58]. Circulating viruses are attacked and inactivated by 
the host’s immune system. Additionally viruses are cleared from the blood by the 
Kupffer cells (liver macrophages). Also, other organs like lung or spleen can 
accumulate virus particles. In the case of adenovirus more than 90% of virus is 
accumulated in the liver. The high level of virus particles can lead to liver toxicity. 
Some strategies to improve delivery and reduce liver tropism have been investigated. 
The pre-treatment with the anticoagulant warfarin combined with depletion of Kupffer 
cells reduced virus levels in the liver and enhanced antitumor activity [59]. Another 
strategy being used is modifying the virus capsid. Certain chimeric constructs have 
shown better tumour infection and lower liver toxicity [60]. Evading the immune 
system is the other essential for effective tumour delivery. Options for preventing 
virus destruction include the use of agents binding and neutralizing antiviral 
antibodies [61]. Direct coating of the capsid with polymer complexes can also be 
used to mask the virus from the immune system [62]. Apart from direct modification 
of the oncolytic viruses a further promising approach is the utilization of cells 
exhibiting tumour tropism as virus carriers. Cell carriers that deliver the virus to the 
tumour shield it from the immune system and additionally should prevent excessive 
liver accumulation and toxicity. One cell type feasible for use as a carrier are cells of 
the immune system, like T-cells and dendritic cells [63]. Besides infecting the tumour 
this cells demonstrate antitumor activity themselves. Other promising carriers are 
adult stem cells. Neural stem cells were shown to deliver oncolytic adenoviruses 
efficiently in an animal model of glioma and prolong survival [64]. Bone marrow 
derived mesenchymal stem cells (MSC) have also been studied for their usability as 
carriers for oncolytic viruses [65].  
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2.4 Mesenchymal stem cells 
Mesenchymal stem cells are multipotent cells, which can be isolated from most 
organs in post-natal vertebrates [66]. They are defined by their ability to differentiate 
into multiple cell types in vitro, like osteoblasts, adipocytes and chondrocytes. In vitro 
they exhibit a fibroblast like morphology and exhibit a characteristic adhesion to 
plastic surfaces under cell culture conditions. Markers expressed by MSC on the cell 
surface include CD105, CD73, CD44, CD90, and CD71. In contrast they do not 
express any hematopoietic markers like CD45, CD14 or CD34 [67]. Being originally 
described to differentiate into various mesenchymal lineages [68], subsequent 
studies could also demonstrate the induction of commitment to non-mesenchymal 
fates. For example, a neural differentiation has been described for MSC [69]. The 
ability to form miscellaneous cell types makes them highly interesting for tissue 
engineering. Currently MSC therapies for various conditions are investigated, 
including bone and cartilage repair, vascular diseases or neurological disorders [70]. 
Additionally the most commonly applied MSC isolating methods, like the isolation 
from the bone marrow of the iliac crest, are minimal invasive and can be performed 
under ambulant conditions. MSC play also a role in cancer progression. They 
integrate into the tumour microenvironment after migrating there. Their migration is 
promoted by secretion of inflammatory signals by the tumour. MSC can both develop 
an pro- or anti-tumour supportive phenotype in the tumour stroma, depending on the 
microenvironment [71]. Additionally MSC modulate the immune reaction to the 
tumour, as they exhibit immunosuppressive effects on various cells of the immune 
system [72].  While their exact role in the tumour is not fully understood, MSC have 
been demonstrated to enhance EMT and CSC stemness in pancreatic cancer [73].  
 
2.5 MSC in tumour therapy 
The migration and integration of MSC into the tumour microenvironment makes them 
excellent candidates for therapy vectors targeting malignant tissues. Combined with 
their immunoprivileged status and their ability to expand inside the tumour they are 
highly promising candidates [74]. As MSC can have anti-oncogenic properties, this 
could be used for interfering with the growth of the cancer. But as the signals leading 
to an anti-oncogenic behaviour in MSC are poorly understood this strategy is still in a 
very early phase [75]. Another option is the use of genetically modified MSC 
expressing anticancer agents. Engineered MSC expressing different therapeutic 
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substances, including Interleukins, IFN-β or TRAIL, have been used in in vivo studies 
against various malignancies [76]. MSC expressing TRAIL, as an example, have 
been used as a second agent for co-treatment of metastatic renal cell carcinoma or 
malignant glioma greatly enhancing therapy efficacy [77, 78]. Another approach is 
the use of MSC as cell carriers for oncolytic virus delivery, as mentioned previously. 
A Phase I clinical trial with MSC transporting oncolytic measles virus to ovarian 
cancer showed promising results. Survival of patients treated with infected MSC was 
significantly increased. This was not true for patients treated with the virus alone [79]. 
A study using MSC for delivery of a conditionally replicative adenovirus demonstrated 
enhanced survival in a mouse model [80]. Furthermore MSC were able to deliver 
oncolytic adenovirus to intracranial glioma xenografts [81]. These findings 
demonstrate the ability of MSC as virus carriers, even reaching poorly accessible 
tumour sites, like in the case of glioma.  
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3. Materials and Methods 
 
3.1 Materials 
 
3.1.1 Equipment and consumables 
96 well suspension culture plates          Greiner bio-one, Frickenhausen 
Accu-jet pro                                           BRAND, Wertheim 
Biosafety cabinet, Napflow 1200           Thermo Fisher Scientific, Waltham, 
USA 
Camera N°241956                                Visitron systems, Puchheim
Cell culture flasks                                  TPP, Trasadingen, Switzerland 
Cell culture plates, 24 well                    TPP, Trasadingen 
Cell culture plates, 6 well                      Greiner bio-one, Frickenhausen                                 
CO2 incubator, Sanyo                           MS Laborgeräte, Wiesloch 
Centrifuge, Biofuge pico                        Heraeus, Hanau 
Centrifuge, Multifuge 3                          Heraeus, Hanau 
Chicken eggs, fertilized                         Hockenberger, Eppingen
Cryotubes                                              Nunc, Wiesbaden 
Decloaking chamber                             Biocare Medical, Concord, USA 
Egg incubator                                        Bruja, Hammelburg 
Falcon tubes                                          Greiner Bio-one, Frickenhausen 
Gloves latex powder free                       Hartmann, Heidenheim  
Gloves nitril powder free                        Ansell, Munich  
Leukosilk S                                            BSN, Hamburg 
Microlance 3 needles                             BD, Heidelberg
Microscope Leica DMRB                       Leica, Wetzlar 
Microscope BIOREVO BZ-9000            Keyence, Neu-Isenburg 
Microtome                                              Leica, Wetzlar 
Neubauer haemocytometer                   BRAND, Wertheim 
Pasteur pipettes                                     Budenberg, Mannheim 
Pipettes, Discovery comfort                   HTL, Warsaw, Poland  
Pipette tips                                             Greiner bio-one, Frickenhausen
Serological pipettes 25ml, 10ml, 5ml     Sarstedt, Nümbrecht 
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Serological pipettes 2ml                        Greiner bio-one, Frickenhausen 
Syringe 5ml                                            BD, Heidelberg 
Syringe, Omnican F 1ml                        BBraun, Melsungen 
Thermanox cover slips                           Nunc, Wiesbaden 
 
3.1.2 Cell culture media and supplements 
Advanced DMEM/F12                             Life Technologies, Darmstadt 
Amphotericin B         Lonza, Verviers, Belgium 
B27 supplement        Life Technologies, Darmstadt 
Biocoll                                                     Biochrom, Berlin
bFGF                                                   Tebu Biotech, Offenbach 
Collagenase Typ IV                                   Worthington Biochemical, Lakewood, 
USA 
Defined K-FSM                                          Life Technologies, Darmstadt 
Dexamethasone                                         Sigma-Aldrich, Taufkirchen  
DMEM (with 4.5 mg/l glucose)                   Sigma-Aldrich, Taufkirchen 
DPBS                                                         Sigma-Aldrich, Taufkirchen
DMSO, 99%                                               Applichem, Darmstadt 
FBS                                                            Sigma-Aldrich, Taufkirchen 
Fibronectin                                                 Sigma-Aldrich, Taufkirchen
hEGF                                                        R&D Systems, Wiesbaden-
Nordenstadt 
HEPES                                                      Sigma-Aldrich, Taufkirchen 
Insulin                                                        Sigma-Aldrich, Taufkirchen
MSC Expansion Media                              Miltenyi, Bergisch Gladbach 
NH Adipodiff Medium                                Miltenyi, Bergisch Gladbach 
NH Chondrodiff Medium                            Milltenyi, Bergisch Gladbach 
NH Osteodiff Medium                                Miltenyi, Bergisch Gladbach 
Penicillin-Streptomycin                              Life Technologies, Karlsruhe 
Trypan blue                                                Biozol, Eching 
Trypsin-EDTA (1x), 0,05%                        Life Technologies, Darmstadt 
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3.1.3 Chemical agents and kits 
Acetic acid, glacial                    VWR, Briare, France
Avidin-Biotin blocking kit                         Linaris, Wertheim-Bettingen 
AEC single solution                                   StemCell Technologies, Köln
BCIP/NBT                                                  Sigma-Aldrich, Taufkirchen 
Bull’s eye decloaker                                   Biocare Medical
Chloroform                                                 Sigma-Aldrich, Taufkirchen 
Collagen, PureCol                                   INAMED, Fremont, USA 
DNAse                                                       Peqlab, Erlangen 
Ethanol                                                      Carl Roth, Karlsruhe
Entellan                                                      Merck, Darmstadt 
Fast Green (FCF)                                      Sigma-Aldrich, Steinheim 
Fluoromount G                                           Biozol, Eching 
Goat serum                                                Alexis, Karlsruhe 
Haematoxylin solution, Mayers                Sigma-Aldrich, Taufkirchen 
Hydrogen peroxide 30%                            AppliChem, Darmstadt  
Hydrochloric acid                                      J.T.Baker, Deventer, Netherlands 
Isopropanol                                               Carl Roth, Karlsruhe 
Matrigel                                                     BD Bioscience, Heidelberg
Methanol                                                   Carl Roth, Karlsruhe 
Methylcellulose                                        Sigma-Aldrich, Steinheim 
Oil Red O                                                  Sigma-Aldrich, Steinheim 
Paraffin (Paraplast)                                   Sigma-Aldrich, Taufkirchen 
Paraformaldehyde                                     Merck, Darmstadt 
Potassium chloride                                    Riedel-de Haen, Seelze 
Potassium dihydrogen phosphate             Merck, Darmstadt 
PKH26 mini kit                                           Sigma-Aldrich, Steinheim 
ProTags Mount Aqua                                BIOCYC, Luckenwalde 
Roti-Histol                                                 Carl Roth, Karlsruhe 
Safranin O                                                 Sigma-Aldrich, Steinheim 
Sodium chloride                                         Riedel-de Haen, Seelze 
Sodium dihydrogen phosphate                  Merck, Darmstadt 
Tween-20                                                  Sigma-Aldrich, Taufkirchen 
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Weigert’s Iron Hematoxylin Set                 Sigma-Aldrich, St. Gallen, Switzerland 
Xylene                                                        
 
Linaris, Wertheim-Bettingen 
 
3.1.4 Buffers and solutions 
10x PBS                                                        2g KCL 
                                                                      2g KH2PO4 
                                                                      14.41g Na2HPO4 x 2H2O 
                                                                      80 g NaCl 
                                                                      Added ddH2O up to 1 L 
                                                                      pH 7.4 
10 x TBS                                                       87.6 g 1.5 M NaCl 
                                                                     12.1 g 100 mM Tris  
                                                                     1 g NaN3 
                                                                      Added ddH2O up to 1 L 
                                                                      pH 7.5 
Single Cell Isolation Medium                        500 ml Advanced DMEM/F 12 
                                                                      10 ml 1 x B27 supplement 
                                                                      20 ng/ml EGF 
                                                                      20 ng/ml basic FGF 
                                                                      0.5 µg/ml dexamethasone 
                                                                      5 µg/ml insulin 
                                                                      5ml Pen/Strep (1:100) 
 
3.1.5.1 Antibodies 
Anti-Adenovirus, mouse                                 
(monoclonal, 1:200) 
Merck Millipore, Darmstadt 
 
  
Anti-CD24 SWA11, mouse                            
(monoclonal, 1:100) 
Kindly provided by Prof. P.Altevogt 
 
 
Anti-Cytokeratin 19, mouse                           
(monoclonal, 1:100)                                        
Abcam, Cambridge, UK 
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Anti-Caspase 3, rabbit  
(polyclonal,1:50)        
R&D Systems, Minneapolis, USA
 
 
Anti-c-Met, rabbit (polyclonal, 1:50) Enzo Life Sciences, Lörrach
 
Anti-Ki67, rabbit (monoclonal, 1:100)             Abcam, Cambridge, UK 
 
Anti-mouse IgG (H+L), biotenylated              
(goat, polyclonal) 
 
Vector Laboratories, Burlington, 
Canada 
Anti-rabbit IgG (H+L), biotenylated                
(goat, polyclonal) 
Vector Laboratories, Burlington, 
Canada 
 
Anti-rabbit IgG, AlexaFluor 488-
conjugated    
Molecular Probes, Karlsruhe
(goat, polyclonal) 
 
Anti-mouse IgG, AlexaFluor 594-
conjugated 
Molecular Probes, Karlsruhe
(goat, polyclonal) 
 
 
3.1.5.2 FITC-conjugated monoclonal antibodies 
Anti-CD34, mouse                                           AdD Serotec, Puchheim, Germany 
Anti-CD44, rat                                                 Novus Biologicals, Cambridge, UK
Anti-CD45, mouse                                           AbD Serotec, Puchheim 
Anti-CD90, mouse                                           AbD Serotec, Puchheim 
Anti-CD105, mouse                                         AbD Serotec, Puchheim 
Anti-CD166, mouse                                          AbD Serotec, Puchheim 
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3.1.6 Oncolytic adenovirus constructs 
All used oncolytic adenoviruses were provided by our cooperation partner Dr Dirk 
Nettelbeck (DKFZ, Heidelberg, Germany). The viral capsid contains a fibre chimera. 
It has the shaft of serotype 5 and the knob domain of serotype 3. All used strains 
contain a gene for GFP, which is expressed by infected cells allowing their 
identification. Oncolytic activity of the different viruses in various pancreatic cell lines 
was examined by our cooperation partner, as were infection rates and virus release 
in MSC. The following virus constructs were used in the present work: 
 
Virus Description 
Ad-SA GFP Control virus [82] 
Ad-CMV Replication incompetent virus [82] 
Ad-IL Control virus; expresses luciferase [83] 
Ad-19K- E1B19K deletion; enhanced cell lysis [83] 
Ad-TRAIL Expresses soluble TRAIL 
Ad-FCU-1 Expresses the suicide gene FCU1 turning a prodrug to 5-FU [84] 
 
 
3.1.7 Cell lines 
Established pancreatic cancer cell lines MIA-PaCa2 and Panc-1 were obtained from 
the American Type Culture Collection (ATCC). 
The primary human pancreatic adenocarcinoma cell line PaCaDD-183 was kindly 
provided by Dr Felix Rückert (University Hospital Mannheim).  
 
 
3.2 Methods 
 
3.2.1 Cell culture methods 
3.2.1.1 Cell culture conditions 
Cells were cultivated in a CO2 incubator at 37°C and 5% CO2. Media were 
supplemented with 10% heat-inactivated FCS and 10mM HEPES, unless stated 
otherwise. Media, DPBS and trypsin solutions were pre-warmed to 37°C prior to use. 
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For determining cell number cells were mixed in a 1:1 ratio with trypan blue solution 
(0.125%) immediately after trypsinisation. Only unstained viable cells were counted 
in an improved Neubauer counting chamber. Cells were seeded in cell culture flasks 
and cultivated until they reached 80-90% confluence. 
 
3.2.1.2 Freezing and thawing of cells 
Cells were trypsinised and cell number was determined. Aliquots of 5x106 – 1x107 
cells were resuspended in medium with 10% (v/v) DMSO. Cryotubes were put in an 
isopropanol-filed cryocontainer and placed in a -80°C freezer. After 24h cells were 
relocated to a -140°C freezer for long-term storage. 
Frozen cells were thawed at 37°C in a water bath. Immediately after thawing cells 
were resuspended in 10 ml of medium and centrifuged. The supernatant was 
resuspended in appropriate medium and seeded in culture flasks. After 24 h medium 
was changed to remove any traces of DMSO. 
 
3.2.1.3 Culture of MIA-PaCa2 and Panc-1 
MIA-PaCa2 cells were cultured in cell culture flasks as adherent cells. DMEM 
medium with 4.5 µg/l glucose and l-glutamine was used for growth of these cells. 
When the cells reached 90% confluence they were trypsinized. After detachment the 
reaction was stopped with serum containing medium. The cells were centrifuged and 
seeded 1:10 in fresh medium into new flasks. 
 
3.2.1.4 Culture of PaCaDD cells 
PaCaDD cells were cultured as adherent cells in cell culture flasks. For culture 
DMEM medium containing 10% heat-inactivated FCS and 10 mM HEPES was mixed 
3:1 with complete K-FSM medium. Cells were passaged when the monolayer 
reached 90% confluence as described under 3.2.1.3 
 
3.2.1.3 Isolation and culture of MSC 
Mesenchymal stem cells were isolated from the bone marrow of healthy donors after 
approval by the ethical board of the University of Heidelberg. Written informed 
consent was obtained from all donors. Bone marrow was obtained from the Iliac crest 
and collected in syringes containing heparin (10,000 IU). The BM solution was diluted 
1:3 with DPBS and filtered through a 100 µm cell strainer. MSC were separated from 
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other components by density gradient centrifugation. 30ml of the BM solution were 
layered on top of 15 ml Biocoll and centrifuged for 40 min at 480 g without brake. 
After centrifugation the MSC-containing red interphase layer was removed and 
resuspended in 50 ml of PBS and centrifuged for 7min at 240 g. After repeating the 
washing step cells were resuspended in stem cell expansion media (containing Pen-
Strep and Amphotericin B) and seeded in flasks coated with 0.1% fibronectin. All 
steps were performed under sterile conditions. 
 
3.2.1.4 Isolation of primary cancer cell spheroids 
Malignant tissue was obtained from patients under the approval of the ethical board 
of the University of Heidelberg. Diagnoses were established by conventional clinical 
and histological criteria according to the World Health Organization (WHO). All 
surgical resections were indicated by principles and practice of oncological therapy. 
Specimens of surgically removed PDAC were minced mechanically and diluted in 
Matrigel. The probes were injected subcutaneously in the flanks of 6-week old female 
NMRI (nu/nu) mice. Developing tumours were resected and subtransplanted to new 
mice. After 3 subtransplantations a stabile growing xenograft line was established. 
For establishing primary cancer cell spheroids resected xenografts were rinsed with 
PBS and minced to ca. 1mm sized pieces under sterile conditions. The minced 
tumour was resuspended in Single Cell Isolation Medium supplemented with 
Collagenase Typ IV (200 U/ml) and DNase (50 U/ml). After 60min incubation at 37°C 
the suspension was filtered through a 100 µm cell strainer to obtain a singe cell 
suspension. Cells were centrifuged and resuspended in fresh Single Cell Isolation 
Medium. Cells were used for experiments within 7 d after isolation. 
 
3.2.2 Differentiation of MSC 
For verifying differentiation potential MSC were trypsinized and seeded in 6-well 
plates coated with 0.1% fibronectin to 80% confluence. Differentiation was induced 
by cultivating the MSC in NH Osteodiff Medium (osteogenic induction) for 2 weeks or 
NH Adipodiff Medium (adipogenic induction) for 3 weeks. MSC cultivated in NH 
Expansion Medium were used as a control. For staining cells were washed with PBS 
and fixed for 5 min with methanol for at RT (adipogenic induction) or with pre-cooled 
methanol at -20°C (osteogenic induction). After fixation cells were washed twice with 
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deionized water and stained to detect differentiated cells. Osteoblasts were stained 
with Sigma Fast BCIP/NBT and adipocytes were stained with Oil Red O solution.  
For chondrogenic induction trypsinized MSC were seeded into a 15 ml Falcon tubes 
(5x105 cells per tube) and centrifuged. Differentiation was induced by cultivation in 
NH Chondrodiff Medium for 3 weeks. Medium was changed every 2-3 days. Pellets 
cultivated in NH Expansion Medium were used as a control. For detection the pellets 
were dehydrated and embedded in paraffin as described under 3.2.5. Slides were 
rehydrated and stained with Weigert’s Iron Hematoxylin for 5 min. The Slides were 
then washed 4 times with distilled water and dipped for a few seconds in Acid EtOH. 
Afterwards probes were washed twice with distilled water and stained with 0.02% fast 
green solution in distilled water for 5 min. Then the slides were rinsed in 1% acetic 
acid solution before being stained with 1% safranin O solution for 30 min. Stained 
slides were cleared twice in 95% ethanol and dehydrated two times in absolute 
ethanol and xylene for 2 min. Dehydrated slides were mounted in Entellan. 
 
3.2.3 Adenovirus infection of cells 
For cell infection viruses were diluted in DMEM containing 2% heat-inactivated FCS 
and 10 mM HEPES to the respective infection titer. Virus titers were measured in 
TCID50. The cells were infected 24 h after seeding as adherent cells. After removing 
the culture medium cells were incubated for 2 h with the virus solution. Afterwards 
medium was changed to the respective culture medium or cells were used 
immediately for experiments.  
 
3.2.4 Colony formation assay 
Cells were trypsinized 24 h after virus infection. After determination of cell number 
cells were seeded in 6-well culture plates at a density of 400 cells per well. Cells 
were incubated for two weeks without changing medium. Afterwards the cells were 
fixated with 3.7% PFA for 10 min and with 70% ethanol for 10 min. After washing with 
distilled water the cells were stained with 0.05% Coomassie Blue for 5 min. Then 
cells were washed with distilled water and dried over night. The number of colonies 
with more than 50 cells was counted under a dissecting microscope. 
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3.2.5 In vitro invasion assay  
MSC were trypsinized and cell number was determined. After marking the cells with 
PKH26 dye (per manufacturers recommendations) 5x104 cells per well were seeded 
into a 24-well plate coated with 0.1% fibronectin. For creation of tumour cell 
spheroids adherent tumour cells were trypsinized and cell number was determined. 
Cells were resuspended in DMEM medium containing 2% heat-inactivated FCS and 
0.25% methylcellulose. 1x104 cells were seeded into 1 well of a 96-well suspension 
culture plate and formed a single spheroid. The MSC were infected with the 
adenovirus constructs 24 h after seeding. Then the MSC were washed four times 
with PBS and layered with 250 µl gel-layer (containing DMEM medium with 2% FCS 
and 0.25% methylcellulose, collagen solution and Matrigel in equal parts). Spheroids 
were placed on top of the gel layer and invasion occurred over night. Then the 
spheroids were removed and placed into a fresh 96-well suspension culture plate. 
Invasion of MSC was evaluated under a BIOREVO BZ-9000 microscope 42 h after 
MSC infection. 
 
3.2.6 Cytospins 
Cells were fixed with 4% PFA for 10min at RT to remove active virus particles. 
Afterwards cells were washed with TBS and with PBS. For centrifugation 100 µl cell 
suspension was placed in a slide chamber. The cells were centrifuged for 4 min at 
400 rpm. Slides were air dried and stored at -20°C. 
 
3.2.7 Immunohistochemistry 
The paraffin-embedded sections were deparaffinised and rehydrated prior to staining. 
They were incubated at 60°C for 15 min, before being transferred to xylene and 
incubated for 15 min. Afterwards the slides were incubated twice in Roti-Histol for 10 
min to remove xylene. For rehydration the slides were incubated twice in 100%, 96% 
and 70% ethanol for 5min each. Finally they were washed with PBS. 
Antigen retrieval was performed by boiling the slides in Bull’s Eye decloaker solution 
in a decloaking chamber at 125°C for 10 min. Antigen retrieval was not performed on 
slides stained with the primary anti-adenovirus antibody. These slides were 
incubated with 0.1% trypsin for 10 min at RT after rehydration. 
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The slides were incubated for 30 min at RT in PBST with 20% goat serum and 4 
drops/ml biotin solution to block unspecific antibody binding. Afterwards the slides 
were incubated for 1 h with the primary antibody in PBS with 4% goat serum and 4 
drops/ml avidin solution. After washing two times with PBST and one time with PBS 
endogenous peroxidase activity was removed by incubation with methanol 
(containing 3% H2O2) for 10 min. After repeating the washing steps the slides were 
incubated with the secondary antibody (diluted 1:200) for 30 min. Subsequently the 
samples were washed and ABC solution (2.5ml PBS containing 1 drop biotin and 1 
drop avidin) was added. After 30 min incubation the sections were washed three 
times with PBS and stained with AEC solution. The staining was stopped after 3-10 
min, when red colouring was detected under a microscope. For stopping the reaction 
slides were put in distilled water. Then a counterstaining with haematoxylin for 3 min 
was performed. The samples were put under tap water to remove the dye and 
washed twice with distilled water before being mounted in ProTaq. Samples without 
the primary antibody were used as negative controls. The samples were evaluated 
under a Leica DMRB microscope. A SPOTTM FLEX 15.2 64Mp camera was used for 
taking pictures. The images were analysed using SPOT Basic/Advanced 4.6 
software. 
 
3.2.8 Immunocytochemistry 
To prevent unspecific antibody binding slides were first incubated in PBST with 20% 
goat serum for 30 min. Afterwards slides were incubated with the first primary 
antibody for 1 h. After washing (two times with PBST, one time with PBS) samples 
were incubated with the appropriate fluorophore-linked secondary antibody for 
30min. Subsequently the samples were washed and incubated with the second 
primary antibody for 1 h. After washing the slides were incubated with an appropriate 
secondary antibody and DAPI (1:50) for 30 min. The samples were washed again 
and mounted in Fluoromount G. Samples in which the respective primary antibody 
was omitted served as a negative control. All steps were performed in the dark. 
Antibodies were diluted in PBS with 4% goat serum. The stained samples were 
examined under a Leica DMRB microscope. Images were captured using a SPOTTM 
FLEX 15.2 64Mp camera and analysed with SPOT Basic/Advanced 4.6 software.  
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3.2.9 Grafting of tumour cells to fertilized chicken eggs 
Tumour cells can be transplanted to the chorioallantoc membrane (CAM) of fertilized 
chicken eggs as a substitute for the use of xenografts grown on mice for in vivo 
experiments. The fertilized chicken eggs were incubated in an egg incubator at 
37.8°C and 45-55% humidity. Eggs were disinfected with pre-warmed 70% ethanol 
before incubation. Eggs were opened 4 d after beginning of incubation. For this eggs 
were punched at the round end of the egg and ca. 3 ml of albumen was removed 
with a syringe. Then a hole with a diameter of ca. 2 cm was cut out in the middle part 
of the egg. After injecting 2 ml of the previously removed albumen into the egg the 
hole was covered by a strip of Leukosilk. The cells were grafted onto the CAM 9 d 
after beginning of incubation. Trypsinized cells were resuspended in medium and 
mixed 1:1 with Matrigel. Rings, which had been cut out of plastic cover slips, were 
placed on the CAM near a blood vessel and 50 µl of cell solution was seeded inside 
the rings. 5x105 cells were seeded per egg. Afterwards the holes were sealed again 
with Leukosilk. 18 days after beginning of incubation tumours were removed and the 
chicken embryos were euthanized with Narcoren injection. Tumour take and tumour 
volume were determined. The volume of tumours was calculated as 
21
3
2
1,
3
4 ddrrV == π . Tumours were fixed in 4% PFA solution over 2-3 days. 
Subsequently the tissue was washed in tap water for 2 h to remove PFA. For 
dehydration the tissue was incubated for 2 h each in ascending strength of alcohol 
(70%, 96%, absolute). After incubation in absolute ethanol over night the tissue was 
incubated with chloroform twice for 2 h. Finally, the tissue was impregnated with 
melted paraffin wax at 60°C over night. Tissue sections were performed with a 
microtome. 
 
3.2.6 Statistical analysis 
The data of the colony-forming assay is presented as mean ± SD of a representative 
experiment with 6 wells per group. The experiment was performed three times 
independently with similar results. Infection of primary CSC spheroids was performed 
three times with similar outcomes. Experiments with transplants in fertilized chicken 
eggs were performed twice with similar results. Representative experiments are 
shown. Groups were compared for tumour volumes of cells transplanted with a 
defined percentage of infected cells using the Kruskal-Wallis test and Mann-Whitney 
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test with a Bonferroni correction. Significance of the data of tumour volumes after 
treatment with adenovirus-infected MSC was evaluated by student’s t test. P < 0.05 
was considered significant. 
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4. Results 
 
The present work was performed in cooperation with the Oncolytic Adenovirus Group 
(DKFZ), which is headed by Dr Dirk Nettelbeck. The Nettelbeck group demonstrated 
a better transduction of both MSC and pancreatic cancer cells by oncolytic 
adenoviruses serotype 5, when a chimeric capsid containing the knob domain of 
serotype 3 was used compared to other examined capsid variants. Therefore this 
capsid was used in further experiments. Moreover, they could show an earlier and 
increased virus release in infected MSC for the modified viruses Ad-TRAIL and Ad-
19K- compared to the Ad-IL virus without improved anti-tumourgenic potential. The 
two modified viruses also exhibited improved oncolytic activity in established and 
primary pancreatic cancer cells. A prodrug-activating virus (Ad-FCU1) showed 
increased oncolytic activity as well if used together with the respective prodrug 5-FC. 
Increase in oncolytic activity varied between different cancer cell lines, indicating 
different sensitivity in the cancer cell lines. The results of our cooperation partner are 
being prepared for publication in an international peer-review journal. The oncolytic 
adenoviruses were provided to our group for further investigation. I tested in my part 
of the project the invasion ability of infected MSC, as well as infection and elimination 
efficiency, especially in regard to CSC. Furthermore I expanded the obtained in vitro 
results in an in vivo model. 	  
4.1 Oncolytic adenovirus infection eliminates tumour-initiating cells 
in vitro 
The elimination of the highly drug-resistant CSC population is essential for a 
successful therapy against pancreatic cancer. A colony formation assay was 
performed to examine if oncolytic adenovirus infection eradicates CSC and not only 
the differentiated cancer cells. As CSC are defined by their ability to grow 
autonomously and to form daughter populations, colony formation is correlated to the 
presence of CSC. An established cell line that harbours a high CSC potential, MIA-
PaCa2, was used for this study. The cells were infected with different virus titres and 
seeded 24 h after infection at low density in cell culture plates. After two weeks no 
colonies had developed in infected populations, even when infection occurred with 
low virus titres (Fig. 11 A, C). If the infected cells were seeded in culture medium 
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containing methylcellulose the number of colonies decreased in a dose-depended 
manner (Fig. 11 B, C). This reflects initial infection rates, as the methylcellulose 
matrix prevents the spread of released virus particles. Thus, the tumour-initiating 
CSC are infected and eliminated by the oncolytic adenovirus.  
 
 
Figure 11: Infection with an oncolytic adenovirus eliminates the CSC population. (A) 
MIA-PaCa2 cells were infected with a virus titre of 5, 15 and 30 TCID50 of the oncolytic Ad-
SA GFP virus. Uninfected cells were used as a control. 200 cells per well were seeded in 6-
well plates 24 h after infection. Colony formation was evaluated after two weeks. Means ± 
SD are shown (**P<0.01). (B) Cells were seeded after infection like previously described in 
medium with 0.25% methylcellulose. Means ± SD of each group are shown (**P<0.01). (C) 
Representative images of plates seeded with or without methylcellulose (+/- Me) and infected 
with different virus titres are shown.  
 
No resistant surviving CSC were observed after infection. Additionally, the surviving 
colonies growing in the methylcellulose-containing medium were eliminated 
completely by a second infection with the oncolytic adenovirus (Fig. 12).  
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Figure 12: Infection with an oncolytic adenovirus eliminates surviving colonies. 
Surviving colonies infected with 5, 15 and 30 TCID50 of the oncolytic Ad-SA GFP virus grown 
in medium with 0.25% methylcellulose were infected with a titre of 5000 TCID50 per plate of 
Ad-SA GFP virus 14 d after initial infection. Plates were fixed 3 d after second infection and 
presence of surviving colonies was evaluated. Representative images of plates with (Ad+, 
lower row) or without (CO, upper row) a second infection are shown.  
  
4.2 MSC isolation and confirmation of identity 
The MSC used in this project were isolated from bone marrow samples obtained 
from healthy donors. The stem cells were isolated from hematopoietic cells by 
gradient centrifugation with Biocoll and subsequent cultivation as plastic-adherent 
cells. The isolated cells grow as a monolayer and exhibited a fibroblast-like 
morphology. To confirm the identity of the cultured bone marrow-derived cells as 
MSC differentiation into cell types from different lineages was induced. The cells 
differentiated readily into osteocytes, adipocytes and chondrocytes (Fig. 13 A).  
Additionally a characteristic marker profile for MSC was verified by FACS analysis 
(Fig. 13 B). The MSC expressed the surface markers CD44, CD90 and CD105, while 
the hematopoietic markers CD34, CD45 and CD166 were absent.  
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Figure 13: MSC properties of isolated bone marrow derived MSC (A) MSC were 
cultivated in NH expansion medium (parental cells) or in the respective differentiation 
medium. Differentiation was confirmed by staining with OilRed O (adipocytes), BCIP/NBT 
(osteocytes) and Fast Green/Safranin O (chondrocytes). (B) MSC were stained with FITC-
conjugated antibodies for characteristic surface markers. Presence of the markers was 
analysed by FACS analysis. 
 
4.3 Oncolytic adenovirus-infected MSC invade tumour spheroids in 
vitro  
For the role as virus carriers for the therapy of PDAC, infection with the oncolytic 
adenovirus is not allowed to interfere with the natural homing ability of the MSC. An 
in vitro invasion assay was performed to ascertain that infected MSC still invade 
tumour tissue. The experiment was performed in medium containing 2% FCS to 
minimize interference of attractants present in the serum with signals released by the 
tumour cells. MIA-PaCa2 and PaCaDD spheroids were formed in methylcellulose 
containing medium. PaCaDD formed globular spheroids with sharp margins, while 
MIA-PaCa2 spheroids were more irregularly shaped. MSC growing as a monolayer 
were marked with a red fluorescence dye and infected with different oncolytic Ad 
strains. The tumour spheroids were separated from the MSC by a gel layer (Fig. 14 
A) consisting of Matrigel, collagen and methylcellulose. The MSC had to migrate 
through the gel layer to reach the tumour spheroids. The spheroids and MSC were 
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co-incubated over night to enable invasion. Afterwards the spheroids were removed 
and placed in fresh wells. Microscopic evaluation occurred around 42 h after 
infection. Infected MSC were detected by green fluorescence due to virus-induced 
GFP expression. The presence of GFP-positive MSC was verified in spheroids from 
each group (Fig. 14 B), demonstrating that infection does not prevent the MSC from 
homing. Infiltration with infected MSC varied strongly between single spheroids. No 
significant differences were noticed between MSC infected with different Ad strains.  
	  	  
31	  
        
	  	  
32	  
             
Figure 14: Invasion of tumour spheroids by oncolytic adenovirus-infected MSC. (A) 
MSC growing as a monolayer were infected with different oncolytic adenoviruses with a virus 
titre of 2000 TCID50 and stained with a red fluorescent dye. After infection the MSC were 
overlaid with a Matrigel/collagen layer. Tumour spheroids were seeded on top of the gel 
layer. Co-incubation occurred over night to allow the MSC to invade the spheroids through 
the gel layer. Afterwards the spheroids were removed and cultivated until 42 h after infection 
before being evaluated under a microscope. (B) Infection control of MSC 42 h after infection. 
Infected cells are identified by GFP expression. GFP is coded by the viral genome. (C) 
Evaluation of invasion in PaCaDD spheroids 42 h after infection. Representative images from 
every group are shown. MSC appear red, virus-infected cells green. (D) Representative 
images of MIA-PaCa2 spheroids with invaded MSC 42 h after infection from every group are 
shown.  
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4.4 Oncolytic adenoviruses infect primary pancreatic CSC 
The ability of the different virus constructs to infect and eliminate pancreatic cancer 
stem cells had been only examined in established cell lines so far. Consistent with 
their previously shown ability to eliminate tumour-initiating cells the control virus Ad-
SA GFP infected CSC in the established pancreatic cell line Panc-1 (Fig. 15). CSC 
were identified by expression of the marker gene c-Met.    
       
              
Figure 15: Oncolytic adenovirus infection of pancreatic CSC. Panc-1 cells were infected 
with a titre of 200 TCID50 of the oncolytic adenovirus Ad-SA GFP. Uninfected cells served as 
a control. Cells were fixed and centrifuged on slides 42 h after infection. Adenoviral capsid 
and c-Met were detected with antibodies by immunocytochemistry. Representative images at 
400x magnification are shown. 
 
To investigate if the viruses are also able to infect CSC in a primary pancreatic 
cancer model, spheroid cultures established from primary mouse xenografts were 
used. The xenografts were established from freshly resected human PDAC tissue 
and were serially subtransplanted on immune deficient nude mice. With increasing 
passage numbers the xenograft tumours exhibited enhanced aggressiveness and an 
enrichment of the CSC markers c-Met and CD133, while maintaining the typical 
morphology of PDAC (Fig. 16 A). The spheroids were infected with oncolytic 
adenovirus after being in culture for two days. Forty-two h after infection the cells 
were centrifuged on slides and Ad infection was detected by staining with an 
antibody against adenoviral capsid proteins. c-Met was used to identify CSC. All of 
the examined adenovirus constructs infected primary CSC spheroids, as seen by c-
Met/adenovirus double positive cells (Fig. 16 B). 
100 µm 
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Figure 16: Infection of primary pancreatic CSC by oncolytic adenoviruses. (A) 
Resected patient PDAC were serially transplanted on mice. The xenografts retained 
morphology of the patient tumour. Tumour spheroids were established from freshly resected 
mouse xenografts and contained a high number of cells positive for the CSC markers c-Met 
and CD133. (B) Primary tumour spheroids were infected with a titre of 200 TCID50 with four 
different oncolytic viruses (Ad-IL, Ad-19K-, Ad-TRAIL, Ad-FCU1). Uninfected spheroids 
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served as a control. Spheroids were fixed and centrifuged on slides 42 h after infection. 
Adenoviral capsid and c-Met were detected with antibodies by immunocytochemistry. 
Representative images at 400x magnification from each group are shown. 
 
4.5 Oncolytic adenovirus infection reduces tumour growth in vivo 
To investigate the effect of oncolytic adenoviral infection in an in vivo model MIA-
PaCa2 cells were transplanted on the CAM membrane of fertilized chicken eggs (Fig. 
17 A). The transplanted tumour cells are innervated and supplied by the blood 
vessels of the CAM and form tumour tissue that exhibits a morphology similar to the 
one found in mouse xenografts, thus allowing to investigate the effect of therapies in 
a highly patient-related model.  The tumour cells were infected in vitro prior to 
engraftment with a high titre of the Ad-SA GFP virus. The transplanted cells 
contained a defined fraction of infected cells (0% (=CO), 1% or 5%). Oncolytic 
adenovirus infection reduced tumour size considerably (Fig. 17 A). Whereas tumour 
size showed large variability in the control group, only small tumours (with the biggest 
being around 200 mm3, compared with around 1000 mm3 for the control group) 
occurred in infected samples. Tumour take (percentage of grafted tumours having 
developed) was only reduced with 5% infected cells. The tumour take of the 1% 
infected cells was comparable to that of the control group. Additionally to smaller size 
infected tumours exhibited a radically altered morphology (Fig. 17 B). While cells 
were organized as a loose tissue in uninfected tumours infected tumours showed 
clusters of densely pact small cells. Both structures contained human cells, as 
confirmed by the presence of human cytokeratin 19. The presence of adenovirus was 
detected only in these clusters (Fig. 17 C) in tumour samples from the 5% group. 
Adenovirus particles could not be attested in the 1% group. To evaluate the effect of 
virus infection on CSC characteristics CD24 was used as a CSC marker. While 
control tumours contained many CD24 positive cells less cell expressing CD24 were 
found in infected tumours. A reduction of the amount of CSC seems to be evoked by 
virus infection (Fig. 17 C). In addition the presence of the proliferation marker Ki67 
was also weaker in the infected tumours (Fig. 17 D). These results suggest that 
oncolytic adenovirus infection reduces proliferation and the amount of cells exhibiting 
CSC characteristics during the development of tumours under in vivo conditions. 
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Figure 17: Effect of infection with an oncolytic adenovirus on tumour growth in vivo 
(A) MIA-PaCa2 cells containing 0% (=CO), 1% or 5% cells infected with Ad-SA GFP were 
transplanted on the CAM of fertilized chicken eggs at day 9 of development. Tumours were 
resected and tumour take (percentage of transplanted tumours which did develop) and 
tumour volume were determined. Mean volume is shown (*P<0.05) (B) Representative 
images at 40x magnification of tissue sections from resected tumours are shown. Sections 
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stained with antibody against virus capsid are shown at magnification. Details of the different 
morphologies are shown at 400x magnification. Sections were stained with a human specific 
antibody against cytokeratin 19 (Cy19). Cy19 positive cells are indicated by arrowheads. (C) 
Location of adenovirus and expression of CD24 were evaluated by immunohistochemistry. 
Arrowheads indicate positive cells. The amount of positive cells is indicated in the white 
boxes. (D) Tumour sections were stained with antibodies against Cy19 and Ki67 for 
evaluation by immunocytochemistry. Nuclei were stained with DAPI. Representative images 
at 400x magnification are shown.  
 
4.6 Ad-infected MSC exhibit tumour tropism in vivo 
The homing of bone marrow-derived MSC to pancreatic tumour xenografts had been 
shown in vivo in previous studies. Transplants of established MIA-PaCa2 cells on the 
CAM of fertilized chicken eggs were used to investigate the invasion ability of MSC 
infected with the various oncolytic adenoviruses. The CAM is intensely vascularized.  
The capillaries found in the CAM form a part of the embryo’s circulatory system. The 
MSC were injected into arteries from the CAM that were carrying blood towards the 
tumour. Prior to injection the MSC were infected in vitro by the miscellaneous Ad 
strains. MSC injection was performed two days before the tumours were resected 
(Fig. 18 A).  
             
Figure 18: Timeline of in vivo invasion of tumour xenografts by infected MSC. 
Experiment is shown with specific steps indicated at respective days of development. 
Tumour cells were grafted at 9 days after beginning of incubation. MSC were injected two 
days before tumour resection, which was performed at incubation day 18, three days before 
the chicken would hatch. 
 
A non-replicating adenovirus (Ad-CMV) was used in a first experiment to establish 
the technique (Fig. 19). The use of Ad-CMV ensured that invaded MSC were not 
lysated before detection. Additionally non-infected MSC were injected as a further 
control group. The presence of MSC did not influence tumour growth compared with 
the other groups. Also the injection procedure did not influence tumour development. 
Infected MSC were detected in tumour samples. Since the invasion of infected MSC 
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was successfully demonstrated in this experiment the replication competent oncolytic 
viruses were used in following experiments.  
 
                        
Figure 19: MSC infected with a non-replicating adenovirus invade tumours in vivo. (A) 
MSC were infected in vitro with a replication incompetent adenovirus (Ad-CMV) and injected 
into CAM arteries leading towards Panc-1 tumour xenografts 2 d before tumour resection. 
Tumour volumes were determined with mean tumour volumes shown. (B) Representative 
images of sections of resected tumours are shown at 400x magnification. Presence of 
infected MSC was detected by immunohistochemistry with antibodies against adenovirus 
capsid. Virus-containing MSC are indicated by arrowheads. 
 
Cells infected with adenovirus were detected in tumour samples from each group 
after injection of infected MSC (Fig. 20) at a very low dissemination. The Ad-positive 
cells were mostly found near the margins of the tumours. No positive cells were 
observed in the control group. Virus injected without MSC (V-CO) was used as a 
control to investigate if the detected infected cells were indeed MSC. The identity of 
infected cells had to be proofed, as the injected MSC could have released virus 
particles into the blood stream. These viruses could possibly be carried to the tumour 
and infect malignant cells there. No infected cells were observed in samples from the 
V-CO group, suggesting that all the detected infected cells were indeed MSC. The 
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obtained results showed that injected, virus-infected MSC reached the tumour and 
where present in the tumour stroma.  
 
            
Figure 20: Oncolytic adenovirus-infected MSC invade tumours in vivo. Tumour cells 
were grafted at 9 days after beginning of incubation. MSC were injected two days before 
tumour resection, which was performed at incubation day 18, three days before the chicken 
would hatch. Representative images of paraffin-embedded tissue sections are shown at 400x 
magnification. Adenovirus infected cells were detected by immunohistochemistry for virus 
capsid. Positive cells were detected in MSC infected with each of the three viruses (Ad-IL, 
Ad-19K- and Ad-TRAIL). No positive cells were observed when virus was administered 
systemically without MSC (V-CO).   
 
4.7 Application of Ad-infected MSC reduces tumour growth in vivo 
Finally, the effect of a treatment by MSC-delivered oncolytic virus was evaluated in 
vivo.  Oncolytic adenovirus-infected MSC were injected in CAM blood vessels two 
days after tumour transplantation. For injection, arteries leading to the tumour were 
chosen. The tumours were collected seven days after MSC injection. As the 
adenovirus lifecycle is two days long, this time should be sufficient for several 
replication and infection cycles. Ad-TRAIL was used as a further control being 
injected without MSC (V-CO) to compare its effect with the respective MSC-delivered 
virus. Whereas Ad-IL had no effect on tumour growth, the other two virus constructs, 
Ad-TRAIL and Ad-19K- reduced tumour growth in vivo (Fig. 21 A). The reduction in 
tumour size is only significant in the Ad-TRAIL treated group. Both Ad-TRAIL and Ad-
19K- also reduced tumour take (percentage of tumours that developed after 
transplantation). The effect was more pronounced with Ad-TRAIL, which also 
strongly reduced tumour size. Tumour size reduction was also observed with V-CO 
treatment. In contrast to the MSC-delivered virus, V-CO treatment did not cause a 
reduction in tumour take and tumour size reduction was not significant. MSC-
delivered infection with Ad-TR and Ad-19K- also decreased proliferation, as evident 
by a lower occurrence of the proliferation marker Ki67 (Fig. 21 B). Additionally, fewer 
cells expressed the CSC marker CD24. Ad-IL infected tumours exhibited less CD24 
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positive cells, but Ki67 presence was not lower than in uninfected tumours. No 
changes in regard to the control group were observed in samples from the V-CO 
group in quantity of these markers. Tumours from the Ad-TR and Ad-19K- groups 
displayed more cells positive for active caspase 3 than found in the other groups, 
indicating induction of apoptosis by infection with these viruses. These findings 
demonstrate that delivery of MSC infected with Ad-TR or Ad-19K- both reduce 
tumour growth, proliferation, and the amount of CSC and elevate apoptosis in vivo, 
with Ad-TRAIL having a more pronounced effect. MSC-delivered infection of Ad-IL in 
contrast showed no effect on the tumour. Compared with MSC-delivered Ad-TR, the 
systemically applied virus exhibited weaker antitumor effects, pointing to a more 
efficient virus delivery by the cell carriers.   
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Figure 21: MSC-delivered oncolytic adenoviruses reduce tumour growth in vivo. (A) 
MSC infected with Ad-IL, Ad-TRAIL or Ad-19K- or Ad-TRAIL without MSC (V-CO) were 
injected in CAM blood vessels at day 11 of embryonic development, 2 days after tumour 
transplantation. MSC were infected with 2000 TCID50. Tumours were resected at day 18. 
Tumour size was measured and tumour volume was calculated. Single tumours are 
represented by dots and mean volume is shown for each group (*P<0.05). (B) 
Immunohistochemical evaluation of sections from paraffin-embedded tumours. 
Representative images of each group are shown at 400x magnification. Positive cells are 
indicated by arrowheads.  
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5. Discussion 
 
5.1 Elimination of pancreatic CSC by oncolytic adenoviruses 
Despite recent progress in pancreatic cancer therapy the survival rates for the 
disease remain among the poorest for major malignancies [3]. The only curative 
treatment available is surgery, which is only possible in early stages of the disease. 
Other present therapies have only palliative functions [2]. The high amount of cells 
with CSC-like characteristics found in pancreatic tumours are thought to be mainly 
responsible for the poor success therapies have had so far [14]. These cells are 
composed of a population that is highly resistant to chemo- and radiation therapy 
[12]. Thus the elimination of the CSC population is a prerequisite for every effective 
therapy [85]. Oncolytic viruses like oncolytic adenovirus represent one promising 
agent being developed for this purpose [30, 31]. In the present study, the use of 
oncolytic adenoviruses for the elimination of pancreatic CSC was investigated. A 
main focus laid on virus delivery using bone marrow derived MSC. The study was 
performed in cooperation with the group of Dr Dirk Nettelbeck (DKFZ), who provided 
and optimized the oncolytic viruses that were used in my work. The group of Dr 
Nettelbeck demonstrated a better transduction of MSC and pancreatic cancer cells 
by viruses with a chimeric capsid, which was subsequently employed for all viruses 
used in this study. They also demonstrated a higher production and release of virus 
particles in MSC for certain armed viruses. These viruses exhibited in addition better 
oncolytic activity in both primary and established pancreatic cancer cells (Data is 
being prepared for publication). However, the assays performed by the group of Dr 
Nettelbeck showed mainly the effects on the bulk of the cancer cell population. 
Therefore, I examined in this work the elimination and infection of CSC. Besides 
elimination of CSC in vitro I demonstrated the infection of highly aggressive primary 
pancreatic CSC spheroids by all examined oncolytic viruses. Further, I successfully 
showed the invasion of tumour cells by oncolytic adenovirus-infected MSC both in 
vitro and in vivo. Finally, the effect of direct oncolytic adenovirus infection as well as 
the application of infected MSC was investigated in an in vivo model. In this model a 
reduction of tumour growth was shown. 
In the present study, a control oncolytic adenovirus (Ad-SA GFP) was able to 
eliminate CSC in vitro completely, as defined by their tumour-initiating potential. The 
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fact that no surviving colonies could be detected even when a virus with no 
modifications increasing anti-tumour activity was used shows the potential of a 
therapy utilizing oncolytic adenovirus. Additionally, this assay ascertains that no CSC 
are resistant to adenovirus infection. This is further highlighted by the case of 
surviving uninfected colonies where methylcellulose prevented infection by released 
virus particles.  Here a second infection with a very low virus concentration killed all 
surviving colonies. The results obtained by me contrast with the efficiency of 
gemcitabine, the most common drug used for pancreatic cancer therapy. Being the 
standard agent for chemotherapy of advanced pancreatic cancer it prolongs patient 
survival only for some months and is unable to efficiently eliminate the malignant cell 
population. Gemcitabine did not eliminate pancreatic CSC completely in reported 
similar assays, even when a sensitising agent was used [86]. This is especially the 
case as MIA-PaCa2, the cell line used in the present work, exhibits a high tolerance 
for gemcitabine. Such a resistance was also observed to build up in cells initially 
vulnerable to gemcitabine treatment [87]. It is a major problem in the clinical setting, 
where build-up of resistance is augmented by certain cell types found in the tumour 
stroma, like macrophages [88]. Thus, oncolytic adenovirus infection shows superior 
efficiency to gemcitabine in the elimination of pancreatic CSC. Moreover a virus 
therapy could be used in cases where the malignant cells have developed a 
resistance to gemcitabine. A resistance to gemcitabine often also results in less 
efficiency when the cells are treated with other cytotoxic agents [89]. The expression 
of multidrug resistance (MDR) proteins by the cancer cells is mostly responsible for 
this resistance to various, even unrelated drugs. This mechanism appears to have no 
effect on virus infection and virus-induced cell lysis [90, 91]. A co-treatment of 
oncolytic adenovirus and cytotoxic drugs like gemcitabine could be proved to have a 
synergistic effect in vivo even in a highly drug- and virus-resistant cell line [92]. Co-
treatment in a mouse xenograft model of ovarian cancer with a combination of a 
modified adenovirus and gemcitabine resulted in an improved survival when 
compared with gemcitabine only treatment [93]. These previous studies and the 
present results suggest that oncolytic adenoviruses can efficiently eliminate 
pancreatic CSC and overcome resistance to conventional cytotoxic agents. 
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5.2 Infection of primary pancreatic CSC by oncolytic adenoviruses 
While oncolytic adenovirus infection showed an excellent performance in established 
cell lines in this study, primary cancer cell lines often differ in their sensitivity to 
therapeutic agents from long established cancer cell lines like MIA-PaCa2 or Panc-1. 
A prolonged cultivation as essentially single-cell organisms can lead to selection of 
cells with specific mutations. The cell culture medium used can also alter cell 
characteristics from the original specimen [94]. Therefore the capability of the 
adenoviruses to infect CSC from primary cell lines was investigated in the present 
work. I examined this ability of four different oncolytic adenovirus strains, a control 
strain containing a luciferase gene (Ad-IL) and three virus constructs with enhanced 
oncolytic activity (Ad-TRAIL, Ad-19K- and Ad-FCU1). The cancer cell spheroids were 
established from resected mouse xenografts of primary human tumours. As only 
CSC can grow as anchorage-independent cells the spheroids represent an almost 
pure CSC population [95]. All of the oncolytic adenoviruses infected the primary CSC 
spheroids. The infection of the CSC cells in particular was demonstrated by the 
presence of cells positive for both adenovirus and c-Met. This demonstrates that also 
patient-derived primary CSC are infected by the viruses. However, the infection rate 
appeared to be lower than in the established cell lines. Thus, the virus concentration 
has likely to be adjusted when primary tumours will be targeted with the oncolytic 
adenoviruses. 
 
5.3 Reduction of tumour growth in vivo by oncolytic adenovirus 
infection  
Malignant cells cultivated in cell culture are often more sensitive to chemotherapy 
agents than cells in tumour tissue in vivo [96]. One cause is the better accessibility to 
cytotoxic agents of cells growing as a monolayer or as a spheroid, as most cells have 
direct contact to the drug-containing medium. This leads also to a better nutrition and 
oxygenation of the cells than in often poorly vascularized tumours. This stressed 
conditions and interaction with host cells increase therapy resistance in tumours. In 
addition, tumour tissue is composed of malignant cells and tumour stroma containing 
necrotic areas and fibrous tissue shielding many tumour cells from chemotherapy [9]. 
Tumour stroma could also be a serious obstacle for virus spread in the tumour. 
Tumour transplants in fertilized chicken eggs form a complex tissue containing 
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stromal cells and blood vessels formed by invaded chicken cells [97, 98]. Therefore, 
it is an excellent model to study therapy delivery and effect in a tumour tissue with a 
morphology resembling that found in patient samples [99]. This model was used in 
the present study to explore the efficiency of the oncolytic viruses in vivo. When 
malignant cells containing a small fraction of oncolytic adenovirus-infected cells were 
transplanted on the CAM of fertilized chicken eggs, the infection reduced tumour size 
considerably. The effect on tumour size correlated with a striking change in tumour 
morphology. While MIA-PaCa2 cells formed a tissue that was mainly composed of 
loosely organised cells, the infected tumours contained several clusters of densely 
packed cells. These clusters contained cells, which were smaller than the cells 
outside of the clusters. While chicken cells, which are present in CAM transplants, 
are smaller than the human malignant cells, the majority of the small cells in the 
clusters were human cells. This was confirmed by their expression of human proteins 
like cytokeratin 19. A rounding of cells after infection with adenovirus has been 
reported previously [100]. Therefore, the cytopathic effect induced by the viral 
infection appears to cause the phenotype observed in my experiment. This is also 
indicated by the fact that virus protein could only be detected in these clusters. Virus 
was not present in each cluster and could only be detected in tumours transplanted 
together with 5% infected cells. So it is likely that a certain threshold exists for the 
detection of virus capsid proteins by the antibody. As virus particles are not big 
enough to be seen directly with optical microscopes, a high concentration is needed 
for a positive staining. Consistent with these results virus infection decreased 
proliferation, as seen by decreased levels of Ki67. Additionally, there were fewer cells 
positive for the CSC marker CD24 in infected tumours. This effect was especially 
pronounced in the dense clusters, where hardly any positive cells were found. The 
absence of CD24 in the clusters points at an efficient elimination of CSC cells by the 
virus also taking place in vivo. My findings are in line with other studies where a 
reduction of the CSC population has been described for several adenoviral vectors 
[101, 102]. The present results show not only the anti-tumorigenic effect of the 
oncolytic virus, but it shows as well that tumour transplants on the CAM of fertilized 
chicken eggs are an excellent model for evaluation of virotherapy in vivo. 
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5.4 Invasion capability of oncolytic adenovirus-infected MSC 
MSC can be easily isolated from adult humans and have been reported to invade 
tumour tissue [74]. These factors make them excellent candidates for transportation 
of cytotoxic agents to tumours [76]. The ability of MSC to invade tumour tissue is 
crucial for their usage as virus carriers. While virus delivery by MSC had been 
demonstrated previously [64, 65] modifications of the used viruses could have had an 
impact on MSC migration. To demonstrate that this ability is still intact after infection 
with the different virus constructs, an in vitro invasion assay was performed by me. 
The infected MSC had to invade tumour spheroids through a gel layer. MSC infected 
with the four different oncolytic viruses (AD-IL, Ad-TRAIL, Ad-19K- and Ad-FCU1) all 
invaded tumour spheroids after infection. No significant differences were observed in 
regard to uninfected control cells. Although a stimulation of MSC migration by TRAIL 
was reported [103], no superior migration ability was validated for the Ad-TRAIL 
infected population in the present study. As TRAIL is expressed mainly in the late 
stage of infection it is very probably not present during the main time point of 
invasion. MSC infected with Ad-19K- were able to invade the tumour spheroids 
similar to MSC from the other groups. Ad-19K- contains a deletion of the anti-
apoptotic E1B19K gen causing an earlier killing of infected cells [54]. MSC infected 
with this virus exhibited a rounded, apoptotic morphology at later time points of 
infection, while cells infected by the other viruses still showed a normal phenotype at 
similar time points. But as MSC migration and invasion occurred right after infection 
the earlier cell death apparently did not interact with the invasion, as shown in this 
study. However, MSC invasion varied strongly between different spheroids. 
Therefore, an exact quantitative analysis of invaded cells could not be performed. 
This was especially true for PaCaDD spheroids, where also many single, floating 
MSC were observed. An explanation could be the more tight and compact 
morphology of these spheroids when compared to MIA-PaCa2 spheroids. This could 
have impeded MSC integration into the spheroids. But also in this situation some 
MSC invaded the PaCaDD spheroids, which demonstrates the homing ability of 
oncolytic adenovirus-infected MSC. These results show that MSC exhibit tumour 
tropism after infection with each of the oncolytic adenoviruses and are suitable 
vectors for their delivery. The present study confirms previous results where homing 
of virus-infected MSC to different tumour types, even ones with poor accessibility like 
glioma, has been demonstrated [80, 81]. 
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5.5 In vivo tumour invasion by oncolytic adenovirus-infected MSC 
The homing ability of infected MSC was studied on tumour transplants in fertilized 
chicken eggs in the present work. The grafted tumours are highly vascularized by 
blood vessels from the CAM and integrated into the blood circulatory system of the 
chicken embryo. The CAM is the place of gas exchange in the developing egg and is 
used for the examination of angiogenesis processes [104]. Therefore it is an ideal 
model for the investigation of MSC homing in vivo. In the present case, infected MSC 
were injected into arteries leading towards the tumour. As the MSC should be 
transported directly to the tumour, they should not have to pass through the whole 
circulatory system. Passing through the embryo would very likely reduce the amount 
of MSC, as they would be stuck in the liver and lung of the embryo. While bleeding 
occurred after injection, it soon stalled and did not harm the embryo. The injected 
MSC could be detected two days after injection in resected tumours. Only a few, 
dispersed infected cells were observed on each section. All MSC were present at the 
margins of the tumours and no MSC were found in central areas of the tumours. No 
infected cells were detected at this time point if virus had been administered without 
MSC. Therefore, delivery with MSC appears to be more efficient than systemic 
injection of virus particles. Moreover, as virus is replicating and released from 
infected cells, a relative small number of MSC could be sufficient for a measureable 
therapeutic effect. My results confirm previous studies done in the mouse model 
where tumour infiltration by oncolytic adenovirus-infected MSC has been 
demonstrated and where MSC-delivered virus was present in the tumour 
microenvironment, while systemic spread was reduced compared to virus injected 
without MSC [105]. Similar results have been achieved with measles virus-infected 
MSC in a mouse model for ovarian cancer [79]. The highly dispersed invasion pattern 
exhibited by the infected stem cells in the present study could be an advantage. In 
another study the direct injection of an oncolytic adenovirus into a tumour xenograft 
on the CAM resulted in only very localized infection [99]. Therefore, a wide 
distribution of initially infected cells should cause a wider dissipation of the virus and 
thus produce many infection hosts throughout the tumour. The ideal cell number for a 
therapy has to be evaluated in a more complex model like rodents and ultimately in 
trials with human patients to establish an efficient therapy protocol for the clinical 
setting.   
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5.6 Therapy with MSC-delivered oncolytic adenoviruses 
A successful virus delivery through bone marrow-derived MSC was successfully 
verified in CAM tumour transplants in the present study. In addition to effective virus 
delivery, the efficacy of the oncolytic viruses in eliminating tumours is a major issue 
determining the overall potency of the therapy. Previous studies reported an anti-
tumour effect of therapies using oncolytic adenovirus, both in vitro and in pancreatic 
cancer xenograft models [106, 107]. In the present study, pancreatic cancer cell 
transplants on the CAM were used to evaluate therapy efficiency and to compare the 
different used adenoviruses. Virus-infected MSC were injected 7 d before tumour 
resection. As the initially infected cells are lysated after 48 h, this time should be 
enough for the spread of the infection. A clear contrast between the efficiency of the 
different used viral constructs was detected. Infection with Ad-IL caused no 
differences in tumour growth when compared to uninfected tumours. Ad-IL does not 
posses enhanced anti-tumour activity. However, a similar virus (Ad-SA GFP) 
exhibited clear CSC eradication in vitro and also in vivo, when the infection was 
present upon transplantation. Reasons for the poor performance in vivo could be a 
low virus spread. This would be especially hindered in this case by the stroma, which 
is composed of chicken cells that cannot be infected by the human-specific virus. In 
addition, existing data points to an important role of the immune system in enhancing 
the anti-tumour activity of oncolytic viruses [36, 108]. The developing chicken embryo 
lacks a fully functional immune system. Therefore, the CAM membrane represents 
an immunologically incompetent model [109]. The immune-compromised state of the 
tumours could therefore lower therapy efficiency, especially in the case of non-armed 
oncolytic viruses. Another critical factor is time or more specifically the duration of the 
therapy. As viral replication takes at least two days viral spread needs a certain time. 
Especially if obstacles like non-infective stroma cells are taken into account. 
Treatment and evaluation in mouse tumour models takes place in a period of a few 
weeks allowing more time for virus replication and spread. In other studies, the effect 
of a therapy has been shown to be more pronounced at later time points exceeding 
one week [106, 110]. An administration of several low doses also proved effective 
against pancreatic cancer tumours [111]. In the present study only a single 
administration was used. In contrast, several treatment rounds would be used 
presumably in a cancer therapy with oncolytic viruses in the clinical setting. In 
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contrast to Ad-IL, the other two viruses, which possess enhanced oncolytic activity, 
displayed a pronounced effect on tumour growth in our model. Both viruses reduced 
tumour size and tumour take. Ad-TRAIL caused a stronger anti-tumorigenic effect 
than Ad-19K-. While both viruses are armed, Ad-19K- is only able to kill directly 
infected cells. Ad-TRAIL on the other hand posses a prominent bystander effect, as 
released TRAIL proteins can induce apoptosis in non-infected cells. The enhanced 
efficiency of oncolytic adenoviruses expressing TRAIL has been demonstrated in 
several studies [39, 112, 113]. While Ad-19K- proofed less efficient on its own, a 
synergistic effect of an E1B19K mutant oncolytic adenovirus together with 
gemcitabine has been described [114]. Therefore Ad-19K- could be suited for use in 
a combination therapy together with DNA-damaging drugs. The anti-tumorigenic 
activity of both armed viruses was additionally confirmed in the present study by a 
reduction of proliferation and CSC markers and elevation of an apoptosis marker. 
Directly administered Ad-TRAIL demonstrated also some therapeutic potential. But 
the effect was not as pronounced as with the MSC-delivered virus. This is shown 
clearly by the lack of influence on the examined markers or on tumour take by the 
directly administered virus. The current data confirms a previous report from a clinical 
trial, where only the MSC-delivered oncolytic viruses increased patient survival [79]. 
In another study a MSC subpopulation even decreased virus immunity in melanoma 
xenografts [115]. Therefore, MSC can likely not only act as virus carriers, but also 
even enhance their therapeutic potential in certain circumstances. Additionally MSC 
prevent virus neutralisation by antibodies. While MSC-delivered oncolytic viruses 
prolonged survival in an immunized mouse model of ovarian cancer naked virus did 
not [65]. This result points to an even more important role of virus carriers in immune-
competent models. A possible immune-competent model for future studies is the 
Syrian hamster. Syrian hamster tissue supports the replication of adenovirus 
serotype 5 well [116]. Therefore the Syrian hamster is a capable model for the study 
of virotherapy. A study in Syrian hamster could demonstrate the induction of tumour-
specific immunity by treatment with adeno- and/or vaccinia virus [111]. The use of 
this model would also enable the study of toxicity and side effects of adenoviral 
treatment. Side effects cannot be assessed in the CAM transplants or in other, more 
commonly used rodents, like mice or rats, as none of this models supports 
adenovirus replication. However, similar oncolytic adenoviruses have been used in 
clinical trials without exhibiting severe toxicity in patients [40, 41]. These 
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to an excellent safety profile of oncolytic adenoviruses as therapeutic agents. From 
the present data, the two viruses with enhanced oncolytic activity, especially Ad-
TRAIL, appear to be the best candidates for further evaluation and therapy 
development. It also shows that the approach with MSC-delivered oncolytic 
adenovirus as a therapeutic agent is superior over directly applied virus and exhibits 
strong anti-tumorigenic effects.  
 
5.7 Conclusion 
The present study demonstrates the efficacy of human bone marrow-derived MSC as 
carriers for oncolytic adenovirus in pancreatic cancer treatment. Oncolytic 
adenoviruses eliminated pancreatic CSC in vitro completely, as was shown by the 
abolition of their colony forming ability. Further, all examined adenoviruses could 
infect highly aggressive CSC from primary tumour spheroids. Therefore, they are 
likely to exhibit a profound activity against pancreatic CSC in a clinical setting. 
Infection with adenoviruses did not interfere with MSC homing in vitro, demonstrating 
the suitability of MSC as virus carriers. Moreover, adenovirus-infected MSC were 
able to invade pancreatic tumour cells and to deliver the virus after injection into 
blood vessels in an in vivo setting. Two evaluated MSC-delivered adenoviruses, Ad-
19K- and Ad-TRAIL, reduced tumour growth in vivo. Additionally they reduced the 
amount of CSC and elevated apoptosis. However, Ad-TRAIL exhibited a superior 
effect. Therefore, MSC-delivered oncolytic adenoviruses are a novel promising 
treatment for the currently incurable pancreatic cancer. A therapy is likely to be 
especially promising if armed viruses with superior anti-tumorigenic potential like 
TRAIL expressing viruses are used. This therapy has the potential to improve the 
poor performance of today‘s pancreatic cancer treatment either on their own or in 
combination with classic cytotoxic agents, like gemcitabine. However, further 
evaluation of therapy parameters like toxicity and virus distribution in mouse or 
similar models will be needed for establishing an effective and save therapy protocol 
before clinical trials can be conducted. 
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